Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $19.63, up 7.39% on the session, giving a market capitalisation of $1.21B. On trailing twelve-month figures it carries a trailing P/E of -5.82, a net margin of 0.0%. Its beta of -0.01 implies it has historically moved less than the broad market.
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
Cullinan Therapeutics, Inc. is most often compared with the following Healthcare names: